Brand Oncology Products1

Product Details:

CAPRELSA^® (vandetanib) Tablets, a kinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.

Additional Information:

• Delivery Time: 3 DAYS
• Packaging Details: AS PER DEMAND

Product Details:

Zytiga (abiraterone) works by reducing androgen production in the body. Androgens are male hormones that can promote tumor growth in the prostate gland.Zytiga is used together with prednisone to treat??prostate cancer??that has spread to other parts of the body.Zytiga is used in men whose prostate cancer cannot be treated with surgery or other medicines.

Product Details:

Tagrisso (Osimertinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.Tagrisso is used to treat a certain type of non-small cell lung cancer. This medicine is used only if your tumor has a specific genetic marker, for which your doctor will test.Tagrisso is usually given after other cancer medicines have been tried without success.

Product Details:

Portrazza (necitumumab) is a recombinant human lgG1 monoclonal antibody developed by Eli Lilly, for the treatment of metastatic squamous non-small cell lung cancer (NSCLC).

Eli Lilly received approval from the US Food and Drug Administration (FDA) for Protrazza in combination with gemcitabine and cisplatin for the treatment of metastatic squamous NSCLC in November 2015. The drug was granted orphan designation by the FDA.

Product Details:

Targretin® (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for oral administration contains 75 mg of bexarotene.

Product Details:

XALKORI is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. It is not known if XALKORI is safe and effective in children.

Product Details:

Ziv-aflibercept is the generic name for the trade name drug Zaltrap. In some cases, health care professionals may use the trade name Zaltrap when referring to the generic drug name ziv-aflibercept.

Drug Type:

Zaltrap is classified as an antineoplastic (anti-cancer) and ­­­­­­­­­vascular endothelial growth factor (VEGF) inhibitor. (For more detail, see “How Zaltrap Works” below)

What Zaltrap Is Used For:

• Treatment of patients with metastatic colorectal cancer. Zaltrap is used in combination with other chemotherapy agents.

Product Details:

Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

• Who have received at least one prior therapy, or
• As first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies .

Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment

Product Details:

Votrient is a type of medicine called a protein kinase inhibitor. It is used to treat kidney cancer that is advanced or has spread to other organs. It works by preventing the activity of proteins that are involved in the growth and spread of cancer cells we are widely acclaimed for offering top notch Votrient to our customers.

Product Details:

Zolinza (vorinostat) is used to treat skin problems caused by cutaneous T-cell lymphoma. Zolinza is usually given after other treatments have been tried without successful treatment. Zolinza may also be used for purposes not listed in this medication guide.

Product Details:

Tykerb (lapatinib) is a cancer medication.

Tykerb is used together with another medicine called capecitabine  or letrozole (Femara) to treat a certain type of advanced breast cancer that has spread to other parts of the body. It is often given after other cancer medications have been tried without successful treatment of symptoms.

Product Details:

LYNPARZA is a prescription medicine used to treat women with advanced ovarian cancer who have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Product Details:

Mozobil (plerixafor injection) is approved by the United States Food and Drug Administration (FDA) to be used with another agent, granulocyte-colony stimulating factor (G-CSF), to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

The safety and efficacy of Mozobil in children has not been established in clinical studies.

How Mozobil Works

Mozobil, in combination with G-CSF, releases hematopoietic stem cells from the bone marrow into the bloodstream by disrupting a bond that normally keeps stem cells anchored to the bone marrow. This enables your healthcare team to collect more stem cells during apheresis.

Product Details:

Nplate® is a man-made protein medicine used to treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP), when certain other medicines, or surgery to remove your spleen, have not worked well enough. Nplate® is not for use in people with a precancerous condition called myelodysplastic syndrome (MDS) or low platelet count caused by any condition other than chronic (lasting a long time) immune thrombocytopenia (ITP). Nplate® is only used if your low platelet count and medical condition increase your risk of bleeding. Nplate® is used to try to keep your platelet count about 50,000 per microliter in order to lower the risk for bleeding. Nplate® is not used to make your platelet count normal. It is not known if Nplate® works or if it is safe in people under the age of 18. - See more at: https://www.nplate.com/patient/about-nplate/index/#sthash.vJud57wY.dpuf

Product Details:

Oncaspar® (pegaspargase) is L-asparaginase (L-asparagineamidohydrolase) that is covalently conjugated to monomethoxypolyethylene glycol (mPEG). L-asparaginase is a tetrameric enzyme that is produced endogenously by E. coli and consists of identical 34.5 kDa subunits. Approximately 69 to 82 molecules of mPEG are linked to L-asparaginase; the molecular weight of each mPEG molecule is about 5 kDa. Oncaspar® activity is expressed in International Units. One International Unit of L-asparaginase is defined as the amount of enzyme required to generate 1 micromole of ammonia per minute at pH 7.3 and 37°C. Oncaspar® is supplied as a clear, colorless, preservative-free, isotonic sterile solution in phosphate-buffered saline, pH 7.3. Each milliliter contains 750 ± 150 International Units of pegaspargase, dibasic sodium phosphate, USP (5.58 mg), monobasic sodium phosphate, USP, (1.20 mg) and sodium chloride, USP (8.50 mg) in water for injection, USP.

Product Details:

ONIVYDE contains a chemotherapy drug called irinotecan, which in its active form interrupts cell reproduction. Irinotecan can be built into a container called a liposome. These liposomes are designed to release the medicine slowly over time.

In the clinical trial that led to FDA approval, ONIVYDE was studied in combination with 2 other drugs called fluorouracil and leucovorin. This combination is referred to as ONIVYDE + 5-FU/LV.

Product Details:

Rituxan (rituximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

Rituxan is used to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Rituxan is also used in combination with another drug called methotrexate to treat symptoms of adult rheumatoid arthritis.

Rituxan is also used in combination with steroid medicines to treat certain rare disorders that cause inflammation of blood vessels and other tissues in the body.

Product Details:

Soliris (eculizumab) is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells.
Soliris is used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinuria (PNH).
Soliris is also used to treat a rare chronic blood disease called atypical hemolytic uremic syndrome (aHUS).
Eculizumab is available only under a special program called Soliris REMS. You must be registered in the program and sign documents stating that you understand the risks and benefits of taking this medication.

Product Details:

Stivarga (regorafenib) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Stivarga is used to treat colorectal cancer. It is also used to treat a rare type of tumor that can affect the esophagus, stomach, or intestines.

Stivarga is usually given after other cancer medications have been tried without success.

Product Details:

YONDELIS® is a prescription medicine used to treat people with liposarcoma or leiomyosarcoma that:

• cannot be treated with surgery or has spread to other areas of the body, and
• who have received treatment with certain other medicines.

Product Details:

ZARXIO is a man-made form of granulocyte colony-stimulating factor (GCSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body???s fight against infection.

Product Details:

Read More... ZERBAXA ceftolozane and tazobactam) is indicated in adult patients for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following Gram-negative microorganisms Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa.ZERBAXA ceftolozane and tazobactam) used in combination with metronidazole is indicated in adult patients for the treatment of complicated intra-abdominal infections (cIAI) caused by the following Gram-negative and Gram-positive microorganisms Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus and Streptococcus salivarius. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA ceftolozane and tazobactam) and other antibacterial drugs, ZERBAXA (ceftolozane and tazobactam) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Rubraca® (rucaparib) tablets are a prescription medicine used for:

 

• the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
• the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

 

Additional Information:

• Minimum Order Quantity: 1 Bottle

Product Details:

TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

• Have disease progression during or following platinum-containing chemotherapy
• Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy